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Background: Although chronic obstructive pulmonary disease is a known cause of secondary polycythemia with 
elevated erythropoietic demands in response to hypoxemia, anemia is relatively common in patients with chronic 
obstructive pulmonary disease and is related to increased mortality. However, little is currently known about the 
relationship between various iron parameters and disease severity in chronic obstructive pulmonary disease pa-
tients.
Methods: Data from the fifth Korean National Health and Nutrition Examination Survey, a population-based epi-
demiologic survey conducted in 2010–2012, were used. A total of 1,129 patients with chronic obstructive pulmo-
nary disease were examined to reveal the associations between the forced expiratory volume in 1 second (FEV1) 
and hemoglobin and iron parameters, including serum iron, ferritin, total iron binding capacity, and transferrin 
saturation, using Spearman correlations and multiple linear regression analyses.
Results: The FEV1 was positively correlated with serum hemoglobin (g=0.37, P<0.001), iron (g=0.20, P<0.001), 
transferrin saturation (g=0.19, P<0.001), and ferritin (g=0.22, P<0.001), and negatively correlated with age (g=-0.40, 
P<0.001) and lower in female patients (g=-0.56, P<0.001) in the Spearman correlation. The FEV1 was independently 
associated with serum iron (b=0.049, P=0.035) and transferrin saturation (b=0.049, P=0.035) after adjusting for age, 
sex, and body mass index in the multiple linear regression analyses.
Conclusion: The serum iron and transferrin saturation levels were independently associated with FEV1 as a marker 
of chronic obstructive pulmonary disease severity.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is characterized by 
chronic inflammation of the airways, lung parenchyma, and pulmo-
nary vasculature, causing airflow limitation that is not fully reversible.1) 
COPD is a known cause of secondary polycythemia with elevated 
erythropoietic demands in response to the consequent hypoxemia. 
However, anemia is relatively common in patients with COPD and is 
related to increased mortality.2) Indeed, anemia-accompanied COPD 
has been shown to be independently related to incremental costs of 
$3,582 per patient per year according to data from United States Medi-
care claims.3)
 A number of previous studies have shown decreased iron availabili-
ty in COPD patients. Low-grade systemic inflammation in COPD may 
represent a possible cause of anemia in this chronic disease.4) More 
specifically, impaired iron availability results from upregulation of fer-
ritin mRNA due to elevations in the levels of inflammatory cytokines 
such as interleukin-1 and interferon-c.5) In addition, certain inflamma-
tory cytokines, such as tumor necrosis factor and interleukin-1, are 
thought to be related to reduced iron utilization,6) and one study sug-
gested the presence of erythropoietin resistance in anemic COPD pa-
tients presenting with high erythropoietin levels, a phenomenon that 
is probably regulated through inflammatory mechanisms.7)
 The iron status in patients with COPD reflects the balance between 
the stimulation of erythropoiesis by hypoxia and its depression by in-
flammation. The present study was conducted to determine whether 
the various iron parameters are associated with the severity of COPD. 
We measured the serum hemoglobin (Hb) and several iron parame-
ters, including serum iron, ferritin, transferrin saturation (TSAT), and 
the total iron-binding capacity (TIBC), in patients with COPD, and 
their relation to the forced expiratory volume in 1 second (FEV1), as an 
indicator of COPD severity.
METHODS
1. Study Design
We performed a cross-sectional cohort study using data from the fifth 
Korean National Health and Nutrition Examination Survey (KNHANES 
V), a nationally representative stratified random sample of the Korean 
population in 2010–2012. A flowchart for the study cohort selection 
procedure is presented in Figure 1. The survey involved subjects aged 
≥40 years who had undergone complete spirometry measurements. 
The exclusion criteria included malignancy, cardiovascular disease, 
admission history due to COPD within the past year, pregnant or nurs-
ing women, white blood cell count of ≥20.0 or ≤3.0×103/mL, pneumo-
nia or active pulmonary tuberculosis on chest radiograph, a restrictive 
or normal pattern identified by pulmonary function test (PFT), or an 
inadequate PFT. The clinical diagnosis of COPD was confirmed using 
the Global Initiative for Chronic Obstructive Lung Disease criteria.8) 
COPD was defined as an FEV1/forced vital capacity ratio <0.70.
2. Measures of Iron Status and Anemia
We examined the Hb level and iron status using laboratory measures 
for serum iron, ferritin, and TIBC. TSAT was calculated as follows: 
KNHANES V
(n=25,534)
No PFT results
(n=2,346)
Aged <40 y
(n=11,873)
Inadequate PFT
(n=1,413)
Normal pattern of PFT
(n=6,472)
Patients with COPD
enrolled into this study
Restrictive pattern of PFT
(n=821)
Obstructive pattern of PFT
(n=1,129)
Malignancy or
CVD or
admission history due to COPD within 1 y or
pregnant or nursing women or
WBC >20.0 or <3.0x10 L or
pneumonia or active pulmonary
Tb on CXR (n=1,480)
3
/
Aged >40 y
(n=12,181)
Figure 1. Flowchart for the study cohort selection procedure. KNHANES V, fifth Korean National Health and Nutrition Examination Survey; CVD, cardiovascular disease; COPD, 
chronic obstructive pulmonary disease; WBC, white blood cells; Tb, tuberculosis; CXR, chest X-ray; PFT, pulmonary function test.
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TSAT (%)=serum iron÷TIBC×100.
3. Statistical Analyses
Data analyses were performed using IBM SPSS Statistics ver. 23.0.0.0 
(IBM Corp., Armonk, NY, USA). The associations between FEV1 and 
the variables were evaluated using Spearman correlations. Multiple 
linear regression analysis was used to evaluate the relationships be-
tween FEV1 and the variables after adjusting for age, sex, and body 
mass index (BMI). Normally distributed continuous variables are ex-
pressed as the mean±standard deviation. Non-normally distributed 
continuous variables are expressed as the median (minimum–maxi-
mum) value. For all analyses, a P-value of less than 0.05 was consid-
ered statistically significant.
RESULTS
1. Characteristics of the Subjects
The baseline characteristics of the cohort are shown in Table 1. The 
median age of the cohort was 66 years (range, 40–91 years). There were 
fewer female (27.55%) than male (72.45%) patients with COPD. The 
proportion of smokers (68.11%) was higher than that of never-smokers 
(30.29%). The median (minimum–maximum) number of smoking 
pack-years was 15 (0–180).
2. Associations of FEV1 with Hemoglobin and Iron 
Parameters in Chronic Obstructive Pulmonary Disease 
Patients
Table 2 shows the Spearman correlation analyses between FEV1 and 
the other variables, including Hb and iron parameters, in patients with 
COPD. The FEV1 was positively correlated with serum Hb (g=0.37, 
P<0.001), iron (g=0.20, P<0.001), TSAT (g=0.19, P<0.001), and ferritin 
(g=0.22, P<0.001), and negatively correlated with age (g=-0.40, P<0.001) 
and lower in female patients (g=-0.56, P<0.001).
3. Relationships of FEV1 with Hemoglobin and Iron 
Parameters in Chronic Obstructive Pulmonary Disease 
Patients
Table 3 shows the multiple linear regression analyses between FEV1 
and the variables, including serum Hb and iron parameters (iron, 
TIBC, TSAT, and ferritin), after adjustment for age, sex, and BMI. The 
multiple linear regression revealed serum iron (b=0.049, P=0.035) and 
TSAT (b=0.049, P=0.035) were independent determinants of FEV1 as 
an indicator of lung function after adjustment for age, sex, and BMI 
(models 1 and 2). Although the levels of Hb, ferritin, and TIBC signifi-
cantly correlated with FEV1 in the Spearman correlation analyses (Ta-
ble 2), they did not correlate with FEV1 after adjustment for age, sex, 
and BMI in the multiple linear regression analyses (Table 3: models 3, 
4, and 5).
DISCUSSION
In this nationwide study, the serum iron and TSAT levels were found 
to be positively related with the FEV1 as an indicator of COPD severity 
after adjustment for age, sex, and BMI; that is, serum iron and TSAT 
negatively correlated with the severity of COPD. This finding indicates 
that the serum iron and TSAT levels could represent biomarkers of 
COPD severity.
 In this study, absolute FEV1 was used to represent the severity of 
COPD and lung function instead of predicted FEV1. The severity of 
airflow limitation in COPD is stratified by the percentage of the pre-
dicted FEV1 in the GOLD classification.8) However, application of the 
Table 1. Baseline characteristics of patients with COPD (N=1,129)
Characteristic Value
Age (y) 66 (40–91)
Sex, n (%)
   Male 818 (72.45)
   Female 311 (27.55)
Body mass index (kg/m2) 23.61±2.85
Smoking status*
   Never smokers 342 (30.29)
   Former smokers 424 (37.55)
   Current smokers 345 (30.56)
Pack-year† 15 (0–180)
Hemoglobin (g/dL) 14.50±1.42
Iron (mg/dL) 118 (15–292)
Total iron-binding capacity (mg/dL) 302 (182–557)
Transferrin saturation (%) 39.38 (4.62–98.63)
Ferritin (ng/mL) 83.58 (4.74–3018.40)
FVC (L) 3.59±0.90
FVC (predicted %) 90.98±13.46
FEV1 (L) 2.28 (0.63–4.76)
FEV1 (predicted %) 79.28 (26.82–136.92)
FEV1/FVC 0.66 (0.25–0.70)
Values are presented as median (range), number (%), or mean±standard deviation.
COPD, chronic obstructive pulmonary disease; FVC, forced vital capacity; FEV1, 
forced expiratory volume in 1 second.
*Data regarding smoking status were missing for 18 subjects. †Data regarding pack-
years were missing for 19 subjects.
Table 2. Correlations between FEV1 and other variables in patients with chronic 
obstructive pulmonary disease
Variable
FEV1 (L)
g* P-value
Age (y) -0.40 <0.001
Sex -0.56 <0.001
Body mass index (kg/m2) 0.06 0.055
Hemoglobin (g/dL) 0.37 <0.001
Iron (mg/dL) 0.20 <0.001
Total iron-binding capacity (mg/dL) 0.02 0.490
Transferrin saturation (%) 0.19 <0.001
Ferritin (ng/mL) 0.22 <0.001
FEV1, forced expiratory volume in 1 second.
*Spearman correlation coefficients.
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predicted FEV1 levels may lead to inappropriate assessments of sever-
ity across different ethnicities, age groups, and sexes. Although patients 
may have the same absolute FEV1 levels, they may be categorized into 
different COPD severity levels depending on the reference equations.9) 
Miller and Pedersen10) found that using absolute FEV1 levels could 
better predict the survival rate compared with the predicted FEV1 val-
ues. Based on our results herein, the serum iron and transferrin satu-
ration levels could be considered as biomarkers to support lung func-
tion as assessed by FEV1 in COPD patients.
 This present study revealed that serum iron and TSAT were associ-
ated with FEV1 after adjustment for age, sex, and BMI in COPD pa-
tients using nationwide data. In a previous study, iron status was found 
to be associated with lung function and disease progression in COPD, 
with lower serum iron and TSAT associated with elevated mortality in 
patients with chronic respiratory failure. In addition, the authors also 
found that TSAT and Hb were independently associated with dys-
pnea.11) Another study showed that reduced iron intake was related 
with an increased risk of COPD and decreased percentage of the pre-
dicted FEV1, though the correlation coefficients were low.12)
 In this study, low serum iron and TSAT were related with severe 
COPD. COPD represents a generalized inflammatory status with ele-
vated production of acute-phase proteins, such as ferritin and hepci-
din, and inhibited iron mobilization from reticuloendothelial iron 
stores, which could result in a functional iron deficiency (ID) despite 
high ferritin levels. Currently, a ferritin cut-off level of <12 ng/mL is 
considered to have a very high specificity for the prediction of absolute 
ID;13) however, the criterion for anemia should be different in patients 
with COPD compared with that in healthy individuals, because the 
pathogenesis of COPD involves a combination of inflammation, hy-
poxemia, and ID. Thus, because there are currently no definite clinical 
Hb or iron parameter cut-off levels for detecting anemia among COPD 
patients, further studies are needed.
 Several studies have shown that the treatment of anemia or ID 
should be considered in COPD patients. Non-anemic ID was found to 
be related to decreased aerobic capacity and a lower pulmonary reha-
bilitation response in COPD patients compared with in patients with 
normal iron status in one previous study.14) Further, some studies have 
shown the benefits of iron supplementation in chronic inflammatory 
disease states such as COPD, congestive heart failure, and chronic kid-
ney disease. Indeed, intravenous iron treatment has been shown to 
improve functional capacity and quality-of-life in chronic kidney dis-
ease15) and heart failure patients with ID, either with or without ane-
mia.16,17) Furthermore, Silverberg et al.18) suggested that dyspnea in 
COPD patients may be improved with the use of erythropoiesis-stimu-
lating agents and intravenous iron to correct for ID.
 Serum iron and TSAT have several advantages as biomarkers in 
COPD, including cost-effectiveness, simplicity, their significant rela-
tionship with FEV1, and relationship with the treatment. Nevertheless, 
Table 3. Multiple linear regression analyses of the factors influencing FEV1 in patients with chronic obstructive pulmonary disease
Variable B* Standard error b† P-value R2 (adjusted R2)‡
Model 1 0.449 (0.447)
   Iron (mg/dL) 0.001 0.0003 0.049 0.035
   Age (y) -0.026 0.002 -0.386 <0.001
   Sex -0.736 0.033 -0.517 <0.001
   BMI (kg/m2) 0.005 0.005 0.020 0.369
Model 2 0.449 (0.447)
   Transferrin saturation (%) 0.002 0.001 0.049 0.035
   Age (y) -0.026 0.002 -0.387 <0.001
   Sex -0.735 0.033 -0.516 <0.001
   BMI (kg/m2) 0.005 0.005 0.022 0.327
Model 3 0.448 (0.446)
   Hemoglobin (g/dL) -0.009 0.013 -0.021 0.455
   Age (y) -0.026 0.002 -0.396 <0.001
   Sex -0.769 0.040 -0.540 <0.001
   BMI (kg/m2) 0.005 0.005 0.021 0.364
Model 4 0.447 (0.445)
   Ferritin (ng/mL) 0.0001 0.0001 0.015 0.529
   Age (y) -0.026 0.002 -0.392 <0.001
   Sex -0.746 0.033 -0.524 <0.001
   BMI (kg/m2) 0.004 0.005 0.019 0.398
Model 5 0.447 (0.445)
   Total iron-binding capacity (mg/dL) 0.0002 0.0003 0.015 0.525
   Age (y) -0.026 0.002 -0.392 <0.001
   Sex -0.752 0.032 -0.528 <0.001
   BMI (kg/m2) 0.004 0.005 0.018 0.441
FEV1, forced expiratory volume in 1 second; BMI, body mass index.
*Un-standardized regression coefficients. †Standardized regression coefficients. ‡Explanatory power of variables on FEV1.
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before routinely using iron supplementation as a treatment, further 
studies should be conducted to examine the risks and effects of iron 
overload toxicity and the appropriate amount of iron for the treatment 
of ID in COPD patients. Further, the fact that polycythemia can lead to 
pulmonary hypertension and venous thromboembolism should be 
considered.19)
 There were some limitations to the present study. Because the 
KNHANES V did not collect data on the C-reactive protein levels, we 
were inevitably not able to exclude subjects with elevated C-reactive 
protein levels, which indicate an acute inflammatory state. To resolve 
this limitation, we excluded subjects with elevated white blood cell 
levels as a marker of the inflammation state. Another major limitation 
is the fact that reversibility tests using bronchodilators were not per-
formed, hence resulting in potential overlap with asthma. However, 
chronic asthma may also demonstrate traits of irreversible airflow ob-
struction and thus be included in the definition of “COPD.”20)
 In conclusion, the serum iron (b=0.049, P=0.035) and TSAT (b=0.049, 
P=0.035) levels were independently associated with FEV1 as a marker 
of COPD severity.
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